FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Published at www.nejm.org September 3, 2008 (10.1056/NEJMe0807372)

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Interventions for the prevention or treatment of disease that are based on our understanding of the pathobiologic features of the illness can provide benefit in how a patient feels or functions or in whether the patient survives. Such benefits are generally achieved through on-target biologic effects of the intervention. However, there are numerous recent cases in which it has been established or strongly suggested that off-target effects of such interventions have adversely altered their risk–benefit profile. For example, in patients with rheumatoid arthritis or osteoarthritis, the cyclooxygenase-2 (COX-2) inhibitors provide an analgesic benefit with a reduced risk of gastrointestinal side . . . [Full Text of this Article]

Source Information

From the Department of Biostatistics, University of Washington, Seattle.

This article (10.1056/NEJMe0807372) was published at www.nejm.org on September 3, 2008. It will appear in the September 25 issue of the Journal.

This article has been cited by other articles:

• Belalcazar, L. M., Raghavan, V. A., Ballantyne, C. M. (2009). Statin-Induced Diabetes: Will It Change Clinical Practice?. Diabetes Care 32: 1941-1943 [Full Text]  
• Rajpathak, S. N., Kumbhani, D. J., Crandall, J., Barzilai, N., Alderman, M., Ridker, P. M. (2009). Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis. Diabetes Care 32: 1924-1929 [Abstract] [Full Text]  
• Califf, R. M., Harrington, R. A., Blazing, M. A. (2009). Premature Release of Data from Clinical Trials of Ezetimibe. NEJM 361: 712-717 [Full Text]  
• Psaty, B. M. (2009). Conflict of Interest, Disclosure, and Trial Reports. JAMA 301: 1477-1479 [Full Text]